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We examined the severity of airway obstruction and the occurrence of respiratory symptoms in a large, nationally
representative population sample and in a subgroup of subjects with chronic bronchitis and/or emphysema to
obtain information for developing national prevention and treatment strategies for these diseases. The study
population comprised of 7217 randomly selected subjects (aged 30 years and older) who participated in a
comprehensive health examination survey. The ‘cases’ were subjects diagnosed as having chronic bronchitis and/or
emphysema. The survey methods comprised of questionnaires, interviews, physical measurements, including
spirometry, and clinical examinations. In the whole study population, the age-adjusted prevalence of chronic
bronchitis and/or emphysema was 22% among men and 7% among women, whilst clinically relevant airways
obstruction (FEV1/FVC% 69) was present in 11% of men and in 5% of women.The occurrence of chronic cough
and phlegm production was lowest among the ‘cases’ with pronounced obstruction (in 68% of men with severe and
in 60% of women with moderate obstruction), whereas cold air-associated dyspnoea aggravation showed an inverse
relationship, occurring most commonly in men ( 80%) with severe obstruction. Unexpectedly, half of the bronchitic
women had never smoked. We conclude that the occurrence of certain bronchitic symptoms, such as chronic cough
and phlegm production and cold air-associated dyspnoea aggravation, may to some degree indicate dierent stages
of the disease. Smoking was not closely associated with airflow limitation in women here.
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Chronic obstructive pulmonary disease (COPD), the most
common chronic respiratory disease in industrialized
countries, is a widely under-rated and under-investigated
disease (1). This has been largely explained by the fact that
the disease cannot be cured (2). The prognosis has been
especially poor in symptomatic patients who continue to
smoke (3). Although COPD develops primarily in smoking
men, even severe COPD has been observed in men and
women who have never smoked (4). Moreover, impaired
lung function has been shown to predict mortality and
morbidity for a range of diseases, both in smokers and in
lifetime non-smokers (5–7).
It is well known that in many patients with even
moderate obstruction the disease has not been diagnosedReceived 14 April 1999 and accepted in revised form 29 September
1999.
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0954-6111/00/040356+08 $35?00/0(8,9). The development of dyspnoea is slow and gradual
and often gives no cause for consulting a doctor until severe
dyspnoea has developed (8).
COPD is characterized by airflow limitation associated
with chronic bronchitis or emphysema (6). Spirometry has
been established as the primary method of diagnosing
COPD and assessing its severity, progression and prog-
nosis. Airway obstruction can be defined as reduced forced
expiratory volume in 1 sec (FEV1) in relation to forced vital
capacity (FVC) or to reference values (9). Attention has
recently been refocused on the value of spirometry as part
of health assessments in middle-aged populations (5).
Information on the severity pattern of airway obstruction
in nationally representative population samples is limited.
Little is also known about the occurrence of respiratory
symptoms in patients with chronic bronchitis and emphy-
sema with respect to the stage of the disease. Such
information is needed, not only for obtaining a better
insight into the natural history of the disease, but also for
developing guidelines for preventive and therapeutic
strategies. The aim of the present study was, firstly, to
examine the severity pattern of airway obstruction in a
large, nationally representative population sample and,# 2000 HARCOURT PUBLISHERS LTD
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in relation to observed obstruction in a subgroup of
subjects with chronic bronchitis and/or emphysema.
Subjects and methods
The present work was part of a large-scale population
study, the Mini-Finland Health Survey, comprising a
nationally representative sample of 8000 persons, 3637
men and 4363 women, aged 30 years or over. The sampling
was performed using a two-stage stratified cluster design.
Randomly selected persons were investigated in each of the
40 study areas representing equitably all parts of the
country, both city and rural areas. The distribution of the
study population by age, marital status and education
closely resembled those for the whole population of the
country. The study consisted of two phases, a screening
phase and a re-examination phase. With the invitation to
attend the screening phase the subjects received a basic
questionnaire including questions on physician-diagnosed
chronic diseases. The clinical examinations, comprising also
symptom interviews, spirometry and X-rays, were per-
formed by a mobile clinic unit. Those with a disease history,
or any symptom or finding suggesting cardiovascular or
respiratory disease, were invited to attend the re-examina-
tion phase a few months later. This included a comprehen-
sive clinical examination by a physician. Smoking habits
were recorded, and those who had been regular smokers
(cigarettes, cigars or pipe tobacco) for at least 1 year and
continued to smoke were defined as current smokers. Those
who had been regular smokers but had quit smoking,
whatever the time-point, were considered former smokers,
and those who had never smoked regularly were classified
as never-smokers.
A standardized questionnaire was used to record
symptoms suggesting respiratory diseases, including dys-
pnoea (10,11). Lung function was measured with the
Vitalograph1 (Vitalograph Ltd., Buckingham, U.K.) spi-
rometer, and the results were corrected to BTPS (body
temperature and pressure, saturated with water vapour).
Results of two technically faultless measurements were
recorded, and the highest readings of FEV1 and FVC were
taken as the final results, whether obtained at the same
measurement or not. The only reason to reject a measure-
ment was a technically incomplete or otherwise unsuccess-
ful blow. The calibration of the spirometer was performed
according to manufacturer’s instructions.
‘Cases’ comprised of all those subjects who, according to
the examining physician, met the criteria of chronic
bronchitis or emphysema or both. Chronic bronchitis was
defined according to the established criteria (12,13) as cough
with phlegm production on most days for at least 3 months a
year during at least 2 consecutive years, excluding other
diseases that could explain the symptoms. Emphysema was
diagnosed on the basis of physical examination and chest
radiographs as permanent abnormal enlargement of the gas-
exchanging airspaces, accompanied by destruction of alveo-
lar wells but not by obvious fibrosis (14,15). Two trained
radiologists independently read all the chest radiographs.Airway obstruction of any degree was defined as FEV1
less than 80% of FVC. The severity of obstruction was
graded as follows—FEV1/FVC%: 70–79%, minimal to
mild; 50–69%, moderate;550%, severe. Only moderate to
severe obstruction (FEV1/FVC% equal to or less than 69)
was considered clinically relevant. For minimal to mild
obstruction, the term ‘mild’ is used in the tables. A total of
7217 (90.2% of the sample) subjects, 3322 men and 3895
women, participated in the study. Spirometric measure-
ments were obtained from 7008 subjects. The subgroup of
‘cases’ comprised a total of 988 subjects, 719 men and 269
women, diagnosed as having chronic bronchitis and/or
emphysema.
STATISTICAL METHODS
Continuous variables are expressed as means (standard
deviation, SD) and prevalences as directly standardized age-
adjusted values. Logistic regression analysis was used to
calculate odds ratios (OR) with 95% confidence intervals
(CI), and these were also used to test the statistical
significance of the dierence between the ‘cases’ and others.
Results
Age distribution and clinical characteristics of the whole
study population and the ‘cases’ are given in Table 1, and
the prevalences of major chronic respiratory diseases by age
group and gender in Table 2. Among the men with chronic
bronchitis and/or emphysema defined as ‘cases’, 521 (72%)
had chronic bronchitis only, 91 (13%) had emphysema only
and 107 (15%) had both diseases. Among women, 239
(89%) had chronic bronchitis only, 24 (9%) emphysema
only and six (3%) had both. The age-adjusted prevalence of
asthma or any other respiratory disease (sarcoidosis, cystic
fibrosis, bronchiectasis and bronchiolitis obliterans) was
3% in both men and women.
The proportion of clinically relevant obstructions was
11% (352 of 3255) among men and 5% (192 of 3753)
among women in the whole population. The respective
figures for the ‘cases’ only were 27% (196 of 719) in men
and 18% (47 of 269) in women. No bronchitic women
suered from severe obstruction and only eight (0.2%) such
women were found in the whole population (Table 3).
Overall, when even minimal to mild changes were taken
into consideration, 47% of men and 39% of women showed
airflow limitation to some degree (Table 3).
The proportion of current smokers was 36% for men and
13% for women in the population, and respectively 72%
and 45% among the ‘cases’ only (Table 1). Table 4 gives the
age-adjusted prevalences of current, former and never-
smokers by severity of airway obstruction. Unexpectedly,
half of the women with chronic bronchitis and/or
emphysema had never been regular smokers.
TABLE 1. Characteristics of subjects with chronic bronchitis and/or emphysema (‘cases’) and the whole study population (all)
‘Cases’ All All
Men Women Men Women
N 719 269 3322 3895
Age distribution, n (%)
30–44 years 206 (29) 83 (31) 1343 (40) 1373 (35)
45–54 177 (25) 55 (20) 781 (24) 828 (21)
55–64 138 (19) 62 (23) 603 (18) 745 (19)
65–74 152 (21) 45 (17) 436 (13) 642 (17)
4 74 46 (6) 24 (9) 159 (5) 307 (8)
Spirometric findings*
FEV1 l mean (SD) 32 (11) 24 (08) 38 (10) 28 (07)
FVC l mean (SD) 43 (12) 31 (08) 48 (11) 34 (08)
FEV1/FVC% mean (SD) 740 (113) 782 (87) 790 (82) 811 (67)
Smoking, n (%)
Current 519 (72) 120 (45) 1206 (36) 497 (13)
Former 136 (19) 12 (5) 1136 (34) 369 (10)
Never 63 (9) 137 (51) 974 (29) 3025 (78)
Cigarettes per day, n (%)
1–9 50 (7) 28 (10) 171 (5) 200 (5)
10–19 155 (22) 50 (19) 421 (13) 182 (5)
20–29 217 (30) 40 (15) 391 (12) 105 (3)
 30 73 (10) 2 (07) 138 (4) 7 (02)
Pipe tobacco/cigars regularly**, n (%) 24 (3) — 85 (3) 3 (008)
Concomitant diseases, n (%)
Cardiovascular 266 (37) 91 (34) 927 (28) 1122 (29)
Other respiratory 55 (8) 31 (12) 141 (4) 159 (4)
Musculoskeletal 338 (47) 150 (56) 1164 (35) 1773 (46)
*data not available in 67 men and 142 women;
**daily or nearly daily.
TABLE 2. Prevalences (%) of major chronic respiratory diseases by age and gender in the whole study population
Age-group (years) 30–44 45–54 55–64 65–74 474 All (age-adjusted)
(n)
Men
Chronic bronchitis 154 218 197 266 193 193 (521)
Emphysema 02 30 91 218 193 61 (91)
Chronic bronchitis and/or
emphysema 154 229 236 364 317 221 (719)
Asthma 06 22 21 22 07 14 (26)
Women
Chronic bronchitis 61 65 84 60 49 65 (239)
Emphysema 00 05 04 18 49 08 (24)
Chronic bronchitis and/or
emphysema 61 67 85 75 99 72 (269)
Asthma 16 26 21 28 37 22 (58)
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TABLE 3. Severity of airway obstruction in men and women according to the presence of chronic respiratory diseases in the
whole study population
Chronic
bronchitis
(only)
Emphysema
(only)
Chronic
bronchitis and/or
emphysema
Asthma or
other chronic
respiratory disease*
No respiratory
disease
All
Men
Airway obstruction, n (%)
None 233 (45) 14 (15) 257 (36) 24 (30) 1459 (59) 1740 (54)
Mild 212 (41) 31 (34) 266 (37) 36 (45) 861 (35) 1163 (36)
Moderate 70 (13) 34 (37) 158 (22) 20 (25) 136 (6) 314 (10)
Severe 6 (1) 12 (13) 38 (5) 0 (0) 0 (0) 38 (1)
Total 521 (100) 91 (100) 719 (100) 80 (100) 2456 (100) 3255 (100)
Any degree of
obstruction, n (%)
288 (55) 77 (85) 462 (64) 56 (70) 997 (41) 1515 (47)
Women
Airway obstruction, n (%)
None 132 (55) 0 (0) 134 (50) 35 (30) 2106 (63) 2275 (61)
Mild 77 (32) 11 (46) 88 (33) 53 (45) 1145 (34) 1286 (34)
Moderate 30 (13) 13 (54) 47 (18) 27 (23) 110 (3) 184 (5)
Severe 0 (0) 0 (0) 0 (0) 3 (3) 5 (01) 8 (02)
Total 239 (100) 24 (100) 269 (100) 118 (100) 3366 (100) 3753 (100)
Any degree of
obstruction, n (%)
107 (45) 24 (100) 135 (50) 83 (70) 1260 (37) 1478 (39)
*sarcoidosis, cystic fibrosis, bronchiectasis or bronchiolitis obliterans.
TABLE 4. Age-adjusted prevalences (%) of current, former and never-smokers according to severity of airway obstruction in
men and women with chronic bronchitis and/or emphysema (‘cases’)
Smoking status
Current Former Never
Men % % %
‘Cases’
Airway obstruction
None 663 200 137
Mild 719 210 71
Moderate 745 197 53
Severe 557 344 99
Total 722 189 88
Other 254 393 352
Whole population 361 343 295
OR (95% CI)* 98 (80–121) 03 (03–04) 02 (01–03)
Women
‘Cases’
Airway obstruction
None 365 56 579
Mild 476 31 493
Moderate 441 58 500
Total 446 45 509
Other 104 98 797
Whole population 131 97 771
OR (95% CI)* 87 (65–117) 06 (04–11) 02 (02–03)
*OD: odds ratio for the dierence between ‘cases’ and others; CI: confidence interval.
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SYMPTOMS IN RELATION TO SEVERITY OF
AIRWAY OBSTRUCTION AMONG THE
‘CASES’
Analysis of the occurrence of respiratory symptoms among
the ‘cases’ stratified by the severity of airflow impairment
revealed that the occurrence of chronic cough and phlegm
production were lowest in subjects with advanced obstruc-
tion (in 68% of men with severe and in 60% of women with
moderate obstruction) (Table 5). In contrast, cold air-
associated aggravation of dyspnoea was reported by most
‘cases’ with severe (80% of men) or moderate (73% of
women) airway obstruction, and in those with no obstruc-
tion, this symptom was experienced by only about one third
of the subjects (35% of men and 30% of women). This
aggravation of dyspnoea was generally more common in
women with obstruction than in such men, even if the
gender dierence did not achieve statistical significance
(Table 5).
Severe dyspnoea (Grades 3–4) was present in 10% of the
bronchitic men, and in 9% of the bronchitic women, and,
TABLE 5. Age-adjusted prevalences (%) of chronic cough
and phlegm production and cold air-associated dyspnoea
aggravation according to severity of airways obstruction in
men and women with chronic bronchitis and/or emphyse-
ma (‘cases’)Chronic cough
and phlegm
production
%
Cold air
associated
dyspnoea
aggravation
%
Men
‘Cases’
Airway obstruction
None 828 354
Mild 842 326
Moderate 814 527
Severe 682 802
Total 836 383
Other 72 112
Whole population 238 165
OR (95% CI)* 420 (321–550) 47 (38–57)
Women
‘Cases’
Airway obstruction
None 961 297
Mild 848 446
Moderate 601 725
Total 870 424
Other 82 170
Whole population 138 186
OR (95% CI)* 393 (268–577) 38 (29–50)
*See legend for Table 4.as expected, was associated with severe airway obstruction.
However, 55% of the bronchitic men with such severe
obstruction had experienced only mild or no dyspnoea at
all (Table 6).
Discussion
AIRWAY OBSTRUCTION
Eleven per cent of all the men and 5% of all the women in
the present study showed clinically relevant airway
obstruction. In agreement with our results, Isoaho et al.
reported a prevalence of 125% for men and 3% for women
in an elderly Finnish population (16). Other studies with
unselected populations from Norway (17) and Denmark
(18) have shown lower prevalences (4–5% for both
genders). However, due to the inconsistency in the
obstruction criteria and age structures of the populations,
any comparison between dierent studies must be taken
with great caution.
It has recently been shown that reduced FEV1 signifi-
cantly increases mortality from all causes, both among men
and women, and that the association persists after
controlling for smoking, age and other risk factors
(5,19,20). The increased risk of death was apparent even
for subjects with relatively mild function impairment (5).
Not even mild impairment without major symptoms should
therefore be ignored. Indeed, no distinct symptoms appear
to occur in most patients with chronic airflow limitation;
the disease may proceed unrecognized until severe and
irreversible loss of FEV1 has occurred (8). Therefore, as our
aim here was to detect even the most subtle changes
associated with early stages of the disease, we included even
minimal to mild obstruction as an own category in the
analysis. Thus, according to the criteria used here, nearly
half of all the men and about 40% of all the women showed
some degree of airways obstruction, although we cannot
exclude the possibility that some of these subjects may have
had undiagnosed asthma, or that in some instances the
findings may have resulted from technically incomplete
spirometry. However, as quality aspects are of utmost
importance in spirometry (21), special attention was
devoted here to quality assurance, calibration of the
spirometer and reproducibility of the measurements. The
severity criteria were based on the FEV1/FVC% values
instead of FEV1% of predicted, because the reference
values for the Finnish population were obtained from a
selected population sample with a spirometry other than
Vitalograph. The ratio of the actual measured values was
considered to be a useful tool for the purpose of this study.
RESPIRATORY SYMPTOMS IN RELATION
TO SEVERITY OF AIRWAY OBSTRUCTION
We found that half of the bronchitic women who had
clinically relevant airways obstruction had never been
regular smokers, indicating that in many women chronic
cough and phlegm production and the development of
TABLE 6. Age-adjusted prevalences (%) of dyspnoea according to severity of airway obstruction in men and women with
chronic bronchitis and/or emphysema (‘cases’)
Grade of dyspnoea**
0–1% 2% 3% 4%
Men
‘Cases’
Airway obstruction
None 663 165 56 81
Mild 754 188 24 31
Moderate 613 296 34 57
Severe 293 254 78 358
Total 694 203 35 61
Other 891 77 13 11
Whole population 858 101 17 21
OR (95% CI)* 03 (02–04) 27 (22–35) 22 (13–38) 46 (28–75)
Women
‘Cases’
Airway obstruction
None 793 136 41 30
Mild 672 225 62 42
Moderate 534 359 41 67
Total 699 211 48 41
Other 826 125 26 17
Whole population 829 128 25 17
OR (95% CI)* 05 (03–06) 18 (13–25) 24 (14–41) 38 (22–66)
*See legend for Table 4; **Dyspnoea Grades: 0–1, none or minimal; 2, mild; 3, moderate; 4, severe according to Rose et al.
(11).
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Similarly, Lundba¨ck et al. have found that a considerable
proportion of women with chronic bronchitis are non-
smokers (22).
Alpha-1-antitrypsin deficiency does not explain our
finding, since the prevalence of the ZZ phenotype of this
deficiency in Finland has been estimated to be only 002%
(23). The possible role of persistent infection (24,25) cannot
be ruled out, neither can that of occupational exposure nor
passive smoking, and these associations may remain
uncovered in men due to the overwhelming impact of
smoking. It is also possible that some asthmatics have been
categorized into ‘cases’, since provocation tests could not be
performed in this large-scale population survey. Asthma
diagnosis was mainly based on anamnesis and a specific
symptom questionnaire. This may also partly explain the
relatively low prevalence of asthma here.
The most important and disabling symptom in COPD
patients is dyspnoea (26). In the Whitehall Study, both
dyspnoea and low FEV1 (percentage of the predicted) were
independent predictors of mortality from chronic respira-
tory and cardiovascular diseases and from all causes (20).
In the present study, more than half of both men and
women with moderate obstruction and more than a quarter
of men in whom obstruction was severe had no patholo-gical (Grades 2–4) dyspnoea. Similar results have been
reported previously (16). Since dyspnoea is the symptom
most likely to lead patients with COPD to seek medical help
(26), the disease is often diagnosed late in its course. Indeed,
a recent health survey of an elderly population revealed that
only about half of the cases with COPD had been
previously diagnosed (16).
Chronic cough and phlegm production was present—
consistently with our diagnostic criteria—in most of the
‘cases’, although these symptoms were less common in
subjects with clinically relevant obstruction than in those
with mild or no obstruction at all. Our results are in
agreement with those of Linde´n et al., who reported that
inflammatory cells are found in bronchoalveolar lavage
(BAL) to a lesser extent in patients with obstructive chronic
bronchitis than in patients with non-obstructive chronic
bronchitis (27). In the more advanced stages of the disease,
the deposition of connective tissue in the epithelium may
not allow the migration of inflammatory cells to the
airspace. This could then result in less phlegm production
and cough in patients with moderate to severe obstruction.
In the landmark study of COPD in working men, Fletcher
et al. (28) found that COPD consists of a hypersecretory
disorder and a distinct obstructive disorder commonly
associated with each other. The main factors determining
362 L. VON HERTZEN ET AL.susceptibility to these disorders are not known, but they are
presumed to be at least partly genetically determined (28).
Mucus hypersecretion alone has not been associated with
increased mortality (29), although recent research has
provided evidence that mucus hypersecretion may be
related to lung function impairment even after adjustment
for baseline FEV1 and smoking status (30). Pathophysio-
logically, symptoms of chronic bronchitis are not consid-
ered to be of any major adverse significance and therefore
chronic bronchitis may rather serve as a harbinger of risk
for the development of obstruction in later life (31). The
subjects with non-obstructive chronic bronchitis did not
actually dier from the population as a whole in any other
aspect than the occurrence of chronic cough and phlegm
production.
Weather (cold air)-associated aggravation of dyspnoea
was related to the severity of the disease. In agreement with
the present study, airway hyper-responsiveness was com-
monly found in patients with COPD, related to the degree
of obstruction (32). Moreover, this symptom has been
associated with the female gender (33) and smoking (33,34).
In the present study, smoking appeared not to be closely
associated with this symptom, since it was especially
common in women with clinically relevant obstruction,
half of whom had never been regular smokers. Obstruction
and hyper-responsiveness may develop independently of
each other, sharing a common cause, for example persistent
inflammation (32). Bronchial hyper-responsiveness present
in COPD seems to dier from that occurring in asthmatic
patients (4,32). Preliminary data from the Lung Health
Study have provided evidence that the use of an inhaled
anticholinergic bronchodilator appears not to influence the
long-term decline of FEV1 in middle-aged smokers with
mild airway obstruction, whereas an intensive smoking
cessation program significantly reduced the decline (35).
We conclude that cold air-associated dyspnoea aggrava-
tion was clearly related to the severity of airways
obstruction, whereas chronic cough and phlegm production
showed an inverse relationship. Factors other than smoking
may also play an important role in the development of
chronic bronchitis and COPD in women.
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